Saturday, November 21, 2009
Fifteen-year prevalence for all the rare tumours, except the Epithelial Tumours of
Cervix Uteri, were under the 50 per 100,000, that is the cut off utilized in Europe for
the definition of rare disease. By contrast, Epithelial Tumours of Oesophagus,
Pancreas, Ovary and Stomach have prevalence rates lower than 50 per 100,000 but
annual incidence rates higher than 6 per 100,000. These four tumors are then
classified as frequent according to our incidence-based definition, but rare according
to the standard EU prevalence-based criterion. All these tumours have very poor
survival and therefore low prevalence figures, even in presence of a relatively high
risk of occurrence, at least for the European population.
National Institutes of Health make it easier to find a clinical trial. | R.A. Bloch Cancer Foundation
"ResearchMatch will match any interested individual residing in the United States with researchers who are approved to recruit potential research volunteers through the system. After an individual has self-registered to become a volunteer, ResearchMatch’s security features ensure that personal information is protected until volunteers authorize the release of their contact information to a specific study that may be of interest to them. Volunteers are notified electronically when they are a possible match and then make the decision regarding the release of their contact information. It also will promote choice as there are no obligations on the volunteer to participate in studies."
Steve Dunn is no longer with us, but his words live on.